Explain this page
Arphra AIPlain-English read on Quest Diagnostics Incorporated’s valuation06-16today
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$290.54
+48.99% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
7bull8bear
±5% threshold
Analyst PT consensus: $220.57 (+13.11%)
Candlestick · 1Y
Open in chart workstation →DGX
195.00+8.68%H 213.50L 164.65MA50 194.86MA200 189.58Avg vol 988K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.40% | -5.12% | +2.42% | +0.43% | +10.76% | +12.37% | +8.68% | +41.26% | +50.66% | +150.51% | +5471.43% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$5.95M
10 txns
Net flow
−$5.95M
Aftermarket
LiveLast trade
$196.23
Bid
$190.27
200 sh
Ask
$209.72
100 sh
Spread
$19.450
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.9B | $252M | $2.24 |
| Q4 Dec 2025 | $2.81B | $245M | $2.18 |
| Q3 Sep 2025 | $2.82B | $245M | $2.16 |
| Q2 Jun 2025 | $2.76B | $282M | $2.47 |
| Q1 Mar 2025 | $2.65B | $220M | $1.94 |
| Q4 Dec 2024 | $2.62B | $222M | $1.95 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$220.57
+13.11% upside
Low
$210.00
Median
$220.00
High
$235.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stockzacks.com·Jun 19, 2026
- Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?zacks.com·Jun 18, 2026
- Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026prnewswire.com·Jun 17, 2026
- Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026prnewswire.com·Jun 17, 2026
- Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Reportprnewswire.com·Jun 16, 2026
- Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Reportprnewswire.com·Jun 16, 2026
- Bullish Quarterly Results: 3 Companies Raising Guidancezacks.com·May 07, 2026
Peers
- UTHRUnited Therapeutics Corporation$570.40$25B
- WSTWest Pharmaceutical Services, Inc.$300.68$21.24B
- LHLabcorp Holdings Inc.$255.84$21.06B
- ILMNIllumina, Inc.$135.78$20.63B
- INCYIncyte Corporation$96.91$19.36B
- WATWaters Corporation$307.12$18.28B
- THCTenet Healthcare Corporation$183.27$16.06B
- ZBHZimmer Biomet Holdings, Inc.$82.90$16.05B
Total assets
$16.23B
Total debt
$6.92B
Cash & equiv
$420M
Operating CF
$1.89B
Free cash flow
$1.36B
Buybacks
-$450M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Plewman Patrick officer: SVP for Diagnostic Services | Sell | 2,855 | $588.73K | Mar 05, 2026 |
PREVOZNIK MICHAEL E officer: SVP & General Counsel | Sell | 3,878 | $799.68K | Mar 05, 2026 |
Doherty Catherine T. officer: EVP, Regional Businesses | Sell | 5,558 | $1.15M | Mar 05, 2026 |
KUPPUSAMY KARTHIK officer: SVP, Clinical Solutions | Sell | 2,628 | $538.37K | Mar 04, 2026 |
PREVOZNIK MICHAEL E officer: SVP & General Counsel | Sell | 526 | $109.27K | Mar 03, 2026 |
Plewman Patrick officer: SVP for Diagnostic Services | Sell | 410 | $85.17K | Mar 03, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $11.04B | $1.6B | $992M | $8.75 | +8.99% |
| FY 2024 | $9.87B | $1.35B | $871M | $7.69 | +8.82% |
| FY 2023 | $9.25B | $1.26B | $854M | $7.52 | +9.23% |
| FY 2022 | $9.88B | $1.43B | $946M | $7.98 | +9.57% |
| FY 2021 | $10.79B | $2.38B | $2B | $15.53 | +18.49% |